GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.
Market
Autoimmune, alloimmune, autoinflammatory and allergic diseases
Location
Boston,
MA,
USA
Coinvestors
Novartis Venture Funds, OrbiMed Advisors, RA Capital Management